Alzheimer's Disease Research Center

总体项目摘要/摘要 这是哥伦比亚大学P30 ADRC的新申请，延续了我们以前的传统 P50 ADRC，自1989年以来一直存在于哥伦比亚大学。在以往成就的基础上，总的目标是 新的ADRC的目的是支持和促进阿尔茨海默病(AD)及其相关的尖端研究 无论是在我们广阔的校园里，还是在全球范围内，我们都在与其他机构和国家财团合作解决混乱问题。 在这一目标范围内，中心将有一个更有重点的主题。主题，重点是“生物学” 与AD发病机制有关的途径，是经过内部讨论后决定的，与我们的 外部咨询委员会成员，以及NIH项目官员。正如在整个提案中所回顾的那样，我们 相信这个宽泛的主题有很多好处。它将通过更好地服务于我们的 基础、翻译和临床研究人员的本地社区；并将生成新的工具和资源，以 我们将与其他机构、财团和组织共享。此外，该主题将允许每个核心 既有与其他ADRC和财团协调的总体目标，也有出现的主题导向目标 来自我们当地的优势。如下文所述，这一主题将使各核心能够在 创建与临床现象学、神经病理学、神经成像和 阿尔茨海默病的基因组学 自30年前成立以来，哥伦比亚的亚洲发展研究中心建立了复杂的基础设施， 研究，促进跨学科合作，建立丰富的培训环境，并促进 外展和病人招募。与此同时，该中心已成为更全球化的 由其他机构、国家财团和社区组织组成的网络。在众多的 在P50 ADRC的周期中，中心已经实现了其大部分目标，例如，其广度证明了这一点 它的科学发现以及它在登记和活跃患者中的高排名。 在这项关于新的P30 ADRC的提案中，我们将在这些先前成就的基础上继续前进，并 将受到两个总体目标的激励。第一个目标是像前几个周期一样，继续促进所有研究 关于AD和相关障碍，而第二个目标是支持这一主题。我们建议实现这些目标 通过我们集成良好的核心，共同建立一个基础设施，以生成丰富的 资源、生物质学家和专业知识。除了行政核心，这些核心还包括临床核心 由劳伦斯·霍尼格博士领导，由霍华德·安德鲁斯博士领导的数据管理和统计核心 由安德鲁·泰奇博士领导的神经病理学核心，由遗传学核心亚当·布里克曼博士领导的生物标记核心 由克里斯蒂安·雷茨博士领导，由菲利普·德·雅格博士领导的神经免疫学核心组织，一个 由William(Ted)Huey博士领导的“Engagement”核心模块和由James Noble博士领导的“研究教育”模块。

OVERALL PROJECT SUMMARY/ABSTRACT This is a new application for a P30 ADRC at Columbia University, continuing the tradition of our previous P50 ADRC that has existed at Columbia since 1989. Building off our prior accomplishments, the overall objective of the new ADRC is to support and promote cutting-edge research on Alzheimer’s disease (AD) and related disorders, both locally in our extensive campus and more globally with other institutions and national consortia. Subsumed within this objective the Center will have a more focused theme. The theme, focusing on ‘biological pathways’ implicated in AD pathogenesis, was decided on after internal deliberations, discussions with our External Advisory Committee members, and with NIH project officers. As reviewed throughout the proposal, we believe that this broad theme has many advantages. It will strengthen the overall objective by better serving our local community of basic, translational, and clinical investigators; and will generate new tools and resources that we will share with other institutions, consortia, and organizations. Additionally, the theme will allow each core to have both general aims that harmonize with other ADRCs and consortia, and theme-guided aims that emerge from our local strengths. As reviewed below, the theme will allow cores to synergize and work together in creating a research infrastructure that relate to the clinical phenomenology, neuropathology, neuroimaging, and genomics of AD. Since its inception 30 years ago, the ADRC at Columbia has established an elaborate infrastructure for research, fostered interdisciplinary collaborations, established a rich training environment, and promoted outreach and patient recruitment. At the same time the Center has become an active participant in a more global network comprised of other institutions, national consortia, and community organizations. During the many cycles of the P50 ADRC, the Center has attained most of its goals, as evidenced, for example, by the breadth of its scientific findings and by its high ranking of enrolled and active patients. In this proposal for a new P30 ADRC we will build off of these prior accomplishments moving forward, and will be motivated by two general goals. The first goal is to continue, as in previous cycles, to foster all research on AD and related disorders, while the second goal is to support the theme. We propose to achieve these goals through our well-integrated cores, which collectively establishes an infrastructure that generates a rich array of resources, biospecimens, and expertise. Besides the Administrative Core, these cores include a Clinical Core led by Dr. Lawrence Honig, a ‘Data Management and Statistical’ Core led by Dr. Howard Andrews, a Neuropathology Core led by Dr. Andrew Teich, a Biomarker Core led by Dr. Adam Brickman, a Genetics Core led by Dr. Christiane Reitz, a Neuroimmunology Core led by Dr. Phillip De Jager, an ‘Outreach, Retention, and Engagement’ Core led by Dr. William (Ted) Huey, and a ‘Research Education’ Module led by Dr. James Noble.